Neurocrine’s schizophrenia drug succeeds at phase 2, but dosing questions remain
Neurocrine Biosciences has achieved late-stage success with muscarinic M4 selective agonist in schizophrenia.
Archives for August 29, 2024
AstraZeneca invests $135M on expanding biologics facility in Sweden
The expansion aims to meet the company’s rapidly growing need for in-house biologics manufacturing, with an emphasis on pre-filled syringe products.
New oral cholera vaccine brings hope for global public health
An international collaboration led by Hilleman Laboratories has confirmed the launch of a new oral cholera vaccine called HILLCHOL, hoping to address significant global shortages.